Core Research

TB-500 Research Overview

TB-500 is a product name that must be resolved to a precise molecular identity before its research can be interpreted. Three different substances commonly appear near the term: the 43-residue parent peptide thymosin-β4, the seven-residue fragment LKKTETQ, and the N-terminally acetylated fragment Ac-LKKTETQ. They are not interchangeable. This overview addresses original analytical, cell and animal work and the limits of applying that literature to a supplied research material.

Research Use Only: Core Research materials are for controlled laboratory research, not human or veterinary use. Neither the published results nor this article provides administration or treatment guidance.

What did the 2012 TB-500 analytical paper identify?

Esposito and colleagues analysed a sample marketed as TB-500 using HPLC and high-resolution mass spectrometry, supported by synthesis and structural comparison. The identified peptide was Ac-LKKTETQ, an N-terminally acetylated heptapeptide corresponding to positions 17–23 in full-length thymosin-β4. “17–23” names the residue positions within the 43-residue parent, not a peptide 17 to 23 residues long.

That finding provides an important chemical example, not a universal market specification. The sample studied by Esposito does not prove that every TB-500 product from every supplier has the same terminal group, counter-ion, purity, content or composition. The original work was primarily an analytical identification study; it did not establish a human repair effect.

Material Chemical identity What can legitimately transfer from the literature?
Thymosin-β4 Full-length 43-residue peptide Parent-specific actin/protein-interaction work, where the same material was tested
LKKTETQ Unacetylated seven-residue sequence Results for the unacetylated fragment in a named cell or animal model
Ac-LKKTETQ N-terminally acetylated seven-residue sequence The analytical TB-500 sample identity and other direct studies of the acetylated fragment

What does parent thymosin-β4 tell us about actin biology?

Thymosin-β4 is a β-thymosin involved in regulation of monomeric actin. The parent peptide contains structural regions absent from a seven-residue fragment. Van Troys and colleagues’ mutational analysis found that the N-terminal region and a central actin-binding region made distinct contributions to parent-peptide interactions. This is why a short motif cannot be presented as a complete functional substitute for full-length thymosin-β4.

A scientist examining cell morphology or migration should distinguish actin-monomer sequestration, changes in cytoskeletal signalling, and the net outcome of a cell-based assay. These are related but not identical measures. Statements such as “TB-500 increases migration” conceal which chemical species, cell type and starting condition were actually tested.

What have fragment studies shown in animal and cellular systems?

Philp and colleagues (2003) investigated full-length thymosin-β4 and a synthetic peptide containing its actin-binding domain in impaired dermal-repair models. In aged mice, the unacetylated LKKTETQ fragment was among the materials examined for repair-associated endpoints. The study did not demonstrate that a supplier’s Ac-LKKTETQ vial reproduces the same biological effects, nor that the animal findings predict human outcomes.

Another direction appears in human hepatic-stellate-cell experiments, where LKKTETQ-related material was studied under PDGF-BB stimulation. Suppressed proliferation and migration were reported in that particular activated-cell context. This is a useful contrast: changes to cell movement can differ by model and stimulus. It is not appropriate to combine the mouse-skin result and the stellate-cell result into a universal “healing” claim.

What changed in the 2024 metabolite study?

Rahaman and colleagues (2024) developed UHPLC–Orbitrap measurements for Ac-LKKTETQ and its metabolites in experimental systems, including human serum and rat samples. In their fibroblast wound-closure screen, the metabolite Ac-LKKTE showed a significant response relative to control where the parent did not show that same reported signal. That finding makes the parent/metabolite distinction experimentally consequential.

The study does not establish that Ac-LKKTETQ is inactive in every system or that Ac-LKKTE is responsible for every reported effect in another study. It shows why metabolite identity, assay conditions and measured endpoint belong beside the headline whenever a result is summarised.

How to compare the evidence correctly

Question Good research interpretation Overstatement to avoid
Which molecule? Specify parent Tβ4, LKKTETQ or Ac-LKKTETQ Call every thymosin-related study “TB-500 evidence”
What model? Named cell, animal or analytical system Treat animal repair endpoints as human efficacy
Which endpoint? Migration, proliferation, signalling, metabolism or chromatography Merge all endpoints into one repair score
Parent or metabolite? Identify the measured chemical species Attribute the active metabolite’s finding to untested parent material
What product? Match the supplied lot to its declared form and analytical record Assume a literature sample authenticates today’s commercial vial

The point of this comparison is attribution: a finding can be informative without answering every other research question. A publication may identify a peptide confidently but measure no biology, or measure an interesting endpoint while not proving the exact commercial molecule’s identity.

What documentation should accompany a TB-500 research material?

An experimental record should distinguish the supplied product name from the documented chemical identity. Where available, examine the declared amino-acid sequence, N-terminal modification, relevant mass assignment and any counter-ion/form statement. Then match the report to the actual product and batch, keeping analytical methods and results separate. HPLC-area percentage alone does not prove molecular identity, and mass confirmation alone does not quantify net peptide content.

The mass-spectrometry guide, HPLC purity guide and CoA-reading guide explain the relevant evidence layers. For current material, use the Batch Documentation route rather than assuming a standard formula from a generic source.

TB-500 catalogue formats and blends

Core Research lists a TB-500 10mg vial, TB-500 Refill 10mg and TB-500 10mg Pen. They are different finished presentations. Shared compound naming does not prove common cartridge compatibility, filled-form analysis or storage stability.

The BPC-157/TB-500 blend introduces a different experimental variable: a mixture. Constituent studies do not demonstrate synergy or a stable ratio in a finished blend. See the TB-500 versus thymosin-β4 comparison and repair-research matrix for related distinctions.

Selected primary research

  1. Esposito S et al. Synthesis and characterization of the N-terminal acetylated 17–23 fragment of thymosin beta 4 identified in TB-500. Drug Testing and Analysis, 2012. DOI: 10.1002/dta.1402. Analytical identity of the particular sample.
  2. Van Troys M et al. The actin binding site of thymosin beta 4 mapped by mutational analysis. EMBO Journal, 1996. PMID: 8617195. Full-length parent-peptide interaction work.
  3. Philp D et al. Thymosin beta 4 and a synthetic peptide containing its actin-binding domain promote dermal wound repair in db/db diabetic mice and in aged mice. Wound Repair and Regeneration, 2003. PMID: 12581423. Animal models and specific fragment.
  4. Shah R et al. Thymosin β4 inhibits PDGF-BB-induced activation, proliferation and migration of human hepatic stellate cells via its actin-binding domain. 2018. PMID: 30063851. Stimulated-cell response.
  5. Rahaman KA et al. Simultaneous quantification of TB-500 and its metabolites and screening of their wound-healing activities in vitro. Journal of Chromatography B, 2024. DOI: 10.1016/j.jchromb.2024.124033. Metabolite-specific findings.